EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy - PubMed
6 hours ago
- #Hypertrophic cardiomyopathy
- #Consensus recommendations
- #Cardiac myosin inhibitors
- Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiac disease, leading to heart failure, arrhythmia, and sudden cardiac death.
- A multidisciplinary panel of experts developed this consensus document, aligning with 2023 ESC and 2024 AHA/ACC guidelines.
- Key sections include phenotypic classification, diagnostic strategies (multimodal imaging, genetic testing), and risk stratification for sudden cardiac death.
- Therapeutic pathways cover pharmacologic treatments (beta-blockers, calcium channel blockers, disopyramide, myosin inhibitors) and septal reduction therapies.
- Management includes atrial fibrillation, hypertension, coronary artery disease, pregnancy, pediatric HCM, and comorbidities.
- Controversies addressed: risk stratification models, care for genotype-positive/phenotype-negative individuals, and exercise recommendations.
- Future directions: gene therapy, precision medicine, artificial intelligence, and novel biomarkers for screening and diagnosis.